| Gene Symbol | RELNPROTEIN |
| Full Name | Reelin |
| Chromosome | 7q22.1 |
| Protein Family | Reelin family |
| Target Class | Signaling Protein |
| Mechanism of Action | Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction. |
| Primary Expression | Cortex, hippocampus, cerebellum |
| Druggability | Low (0.33) |
| Clinical Stage | Approved |
| Molecular Weight | ~388 kDa (full-length) |
| Amino Acids | 460 aa |
| UniProt ID | P78536 |
| GeneCards | RELNPROTEIN |
| Human Protein Atlas | RELNPROTEIN |
| Associated Diseases | AD, Als, Alzheimer, Alzheimer disease |
| Known Drugs/Compounds | valproic acid |
| Interactions | AD, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID, APOE, APOE3 |
| SciDEX Target | View Target Profile (9 clinical trials) |
| SciDEX Hypotheses | Reelin-Mediated Cytoskeletal Stabilization Protoco |
| KG Connections | 295 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!